Bellerophon Therapeutics, Inc. - FORM S-1 - EX-23.1 - January 13, 2015

Attached files

file filename
S-1 - S-1 - Bellerophon Therapeutics, Inc.a2222456zs-1.htm
EX-10.20 - EX-10.20 - Bellerophon Therapeutics, Inc.a2222456zex-10_20.htm
EX-10.18 - EX-10.18 - Bellerophon Therapeutics, Inc.a2222456zex-10_18.htm
EX-10.10 - EX-10.10 - Bellerophon Therapeutics, Inc.a2222456zex-10_10.htm
EX-10.13 - EX-10.13 - Bellerophon Therapeutics, Inc.a2222456zex-10_13.htm
EX-10.2 - EX-10.2 - Bellerophon Therapeutics, Inc.a2222456zex-10_2.htm
EX-10.15 - EX-10.15 - Bellerophon Therapeutics, Inc.a2222456zex-10_15.htm
EX-10.21 - EX-10.21 - Bellerophon Therapeutics, Inc.a2222456zex-10_21.htm
EX-10.14 - EX-10.14 - Bellerophon Therapeutics, Inc.a2222456zex-10_14.htm
EX-10.17 - EX-10.17 - Bellerophon Therapeutics, Inc.a2222456zex-10_17.htm
EX-10.12 - EX-10.12 - Bellerophon Therapeutics, Inc.a2222456zex-10_12.htm
EX-10.11 - EX-10.11 - Bellerophon Therapeutics, Inc.a2222456zex-10_11.htm
EX-10.1 - EX-10.1 - Bellerophon Therapeutics, Inc.a2222456zex-10_1.htm
EX-10.9 - EX-10.9 - Bellerophon Therapeutics, Inc.a2222456zex-10_9.htm
EX-10.22 - EX-10.22 - Bellerophon Therapeutics, Inc.a2222456zex-10_22.htm
EX-10.4 - EX-10.4 - Bellerophon Therapeutics, Inc.a2222456zex-10_4.htm
EX-10.8 - EX-10.8 - Bellerophon Therapeutics, Inc.a2222456zex-10_8.htm
EX-10.3 - EX-10.3 - Bellerophon Therapeutics, Inc.a2222456zex-10_3.htm
EX-10.19 - EX-10.19 - Bellerophon Therapeutics, Inc.a2222456zex-10_19.htm
EX-10.23 - EX-10.23 - Bellerophon Therapeutics, Inc.a2222456zex-10_23.htm
EX-21.1 - EX-21.1 - Bellerophon Therapeutics, Inc.a2222456zex-21_1.htm

Exhibit 23.1

 

Consent of Independent Registered Public Accounting Firm

 

The Board of Directors
Bellerophon Therapeutics LLC:

 

We consent to the use of our report dated May 14, 2014, except for note 13(a), which is as of January 8, 2015, with respect to the financial statements of Bellerophon Therapeutics LLC as of December 31, 2013 and 2012 and for the years then ended and for the period from August 26, 2009 (inception) to December 31, 2013, included herein and to the reference to our firm under the heading “Experts” in the prospectus.

 

 

/s/ KPMG LLP

 

Short Hills, New Jersey

January 13, 2015

 


Bellerophon Therapeutics, Inc. Reports

Also read